Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Beam Therapeutics (BEAM) EBITDA Margin (2019 - 2025)

Beam Therapeutics (BEAM) has disclosed EBITDA Margin for 7 consecutive years, with 214.37% as the latest value for Q4 2025.

  • Quarterly EBITDA Margin rose 51847.0% to 214.37% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 56.93% through Dec 2025, up 53608.0% year-over-year, with the annual reading at 56.93% for FY2025, 53608.0% up from the prior year.
  • EBITDA Margin for Q4 2025 was 214.37% at Beam Therapeutics, up from 1154.34% in the prior quarter.
  • The five-year high for EBITDA Margin was 214.37% in Q4 2025, with the low at 3359583.33% in Q1 2021.
  • Average EBITDA Margin over 5 years is 232178.22%, with a median of 676.99% recorded in 2022.
  • The sharpest move saw EBITDA Margin crashed -284595000bps in 2021, then surged 335873095bps in 2022.
  • Over 5 years, EBITDA Margin stood at 126.84% in 2021, then crashed by -42bps to 180.19% in 2022, then soared by 126bps to 45.99% in 2023, then crashed by -761bps to 304.1% in 2024, then surged by 170bps to 214.37% in 2025.
  • According to Business Quant data, EBITDA Margin over the past three periods came in at 214.37%, 1154.34%, and 1210.03% for Q4 2025, Q3 2025, and Q2 2025 respectively.